Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10355
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNorman, Trevor Ren
dc.contributor.authorMorse, C Aen
dc.contributor.authorDennerstein, Len
dc.date.accessioned2015-05-15T23:46:55Z
dc.date.available2015-05-15T23:46:55Z
dc.date.issued1991-12-01en
dc.identifier.citationFertility and Sterility; 56(6): 1034-9en
dc.identifier.govdoc1743318en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10355en
dc.description.abstractTo study the pharmacokinetics of progesterone (P) in healthy premenopausal female volunteers to compare the bioavailability of orally or vaginally administered hormone.Subjects were randomly allocated to receive either oral P or a vaginal pessary then crossed over to the alternate preparation 1 month later.The study was conducted in outpatient setting.All subjects were healthy, normal female volunteers who underwent a physical and gynecological examination before the study. None were using oral contraceptives. Ten subjects (mean age 32.6 +/- 7.3 years) entered the study and all completed it.Progesterone was administered as 200 mg of micronized hormone or as a pessary containing 400 mg.Plasma levels of P were measured by radioimmunoassay to test the apriori hypothesis of similar bioavailability.Peak plasma P concentrations attained within 4 hours after oral administration ranged from 8.5 to 70.6 ng/mL, whereas after vaginal administration the peak levels were attained within 8 hours and ranged from 4.4 to 181.1 ng/mL. Considerable interindividual variation was noted. Area under the plasma concentration-time curve for the two formulations was not significantly different (F = 1.09; P greater than 0.1; ANOVA).The two formulations had similar bioavailability.en
dc.language.isoenen
dc.subject.otherAustraliaen
dc.subject.otherBiologyen
dc.subject.otherData Analysisen
dc.subject.otherDeveloped Countriesen
dc.subject.otherEndocrine Systemen
dc.subject.otherExaminations And Diagnosesen
dc.subject.otherHormonesen
dc.subject.otherLaboratory Examinations And Diagnosesen
dc.subject.otherOceaniaen
dc.subject.otherPhysiologyen
dc.subject.otherProgestational Hormonesen
dc.subject.otherProgesterone--administraction and dosageen
dc.subject.otherProgesterone--pharmacodynamicsen
dc.subject.otherProgesterone--side effectsen
dc.subject.otherResearch Methodologyen
dc.subject.otherAdministration, Oralen
dc.subject.otherAdulten
dc.subject.otherAnalysis of Varianceen
dc.subject.otherBiological Availabilityen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherOsmolar Concentrationen
dc.subject.otherPessariesen
dc.subject.otherProgesterone.administration & dosage.blood.pharmacokineticsen
dc.subject.otherRandom Allocationen
dc.titleComparative bioavailability of orally and vaginally administered progesterone.en
dc.typeJournal Articleen
dc.identifier.journaltitleFertility and sterilityen
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages1034-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1743318en
dc.type.austinJournal Articleen
local.name.researcherNorman, Trevor R
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptPsychiatry (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Jan 14, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.